| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Emergency Service, Hospital | 148 | 2024 | 1088 | 11.420 |
Why?
|
| Heart Failure | 129 | 2025 | 2285 | 9.930 |
Why?
|
| Acute Coronary Syndrome | 47 | 2024 | 215 | 7.420 |
Why?
|
| Myocardial Infarction | 66 | 2024 | 1018 | 7.310 |
Why?
|
| Troponin I | 36 | 2024 | 103 | 5.690 |
Why?
|
| Hyperkalemia | 11 | 2023 | 66 | 5.370 |
Why?
|
| Natriuretic Peptide, Brain | 43 | 2025 | 312 | 4.840 |
Why?
|
| Rivaroxaban | 24 | 2020 | 55 | 4.810 |
Why?
|
| Pulmonary Embolism | 26 | 2025 | 177 | 4.600 |
Why?
|
| Troponin T | 30 | 2023 | 282 | 4.220 |
Why?
|
| Biomarkers | 93 | 2025 | 3069 | 3.950 |
Why?
|
| Chest Pain | 31 | 2022 | 126 | 3.920 |
Why?
|
| Dyspnea | 25 | 2022 | 152 | 3.430 |
Why?
|
| Hemorrhage | 24 | 2024 | 468 | 3.410 |
Why?
|
| Factor Xa Inhibitors | 16 | 2020 | 64 | 3.400 |
Why?
|
| Electrocardiography | 56 | 2021 | 975 | 3.180 |
Why?
|
| Stethoscopes | 5 | 2024 | 7 | 2.960 |
Why?
|
| Hospitalization | 41 | 2025 | 1780 | 2.950 |
Why?
|
| Acute Disease | 75 | 2025 | 1110 | 2.840 |
Why?
|
| Risk Assessment | 62 | 2024 | 3449 | 2.830 |
Why?
|
| Anticoagulants | 24 | 2024 | 592 | 2.730 |
Why?
|
| Aged | 189 | 2025 | 19835 | 2.540 |
Why?
|
| Humans | 381 | 2025 | 124906 | 2.410 |
Why?
|
| Middle Aged | 195 | 2025 | 26879 | 2.340 |
Why?
|
| Stroke | 16 | 2020 | 987 | 2.320 |
Why?
|
| Troponin | 16 | 2024 | 77 | 2.280 |
Why?
|
| Patient Discharge | 26 | 2023 | 490 | 2.240 |
Why?
|
| Male | 243 | 2025 | 61395 | 2.060 |
Why?
|
| Emergency Medical Services | 15 | 2021 | 437 | 1.990 |
Why?
|
| Prospective Studies | 81 | 2025 | 6155 | 1.970 |
Why?
|
| Venous Thromboembolism | 10 | 2025 | 166 | 1.920 |
Why?
|
| Length of Stay | 35 | 2024 | 1311 | 1.890 |
Why?
|
| Female | 240 | 2025 | 66678 | 1.880 |
Why?
|
| Practice Guidelines as Topic | 32 | 2021 | 1269 | 1.830 |
Why?
|
| Guideline Adherence | 19 | 2021 | 382 | 1.790 |
Why?
|
| Emergency Medicine | 13 | 2016 | 154 | 1.780 |
Why?
|
| Atrial Fibrillation | 13 | 2018 | 659 | 1.780 |
Why?
|
| Cardiology | 12 | 2024 | 504 | 1.740 |
Why?
|
| Aged, 80 and over | 82 | 2025 | 6588 | 1.720 |
Why?
|
| Patient Readmission | 15 | 2020 | 385 | 1.720 |
Why?
|
| Hospital Mortality | 33 | 2024 | 1024 | 1.680 |
Why?
|
| Registries | 43 | 2020 | 1430 | 1.620 |
Why?
|
| Antihypertensive Agents | 10 | 2015 | 412 | 1.550 |
Why?
|
| Cross Infection | 4 | 2023 | 323 | 1.540 |
Why?
|
| Emergency Treatment | 9 | 2020 | 87 | 1.480 |
Why?
|
| Galectin 3 | 5 | 2015 | 36 | 1.470 |
Why?
|
| Hypertension | 15 | 2020 | 1324 | 1.450 |
Why?
|
| Vasodilator Agents | 12 | 2015 | 204 | 1.420 |
Why?
|
| Dabigatran | 7 | 2019 | 27 | 1.350 |
Why?
|
| Thromboembolism | 3 | 2022 | 89 | 1.320 |
Why?
|
| Brain Concussion | 3 | 2024 | 229 | 1.310 |
Why?
|
| Hand Hygiene | 3 | 2023 | 13 | 1.260 |
Why?
|
| Peptide Fragments | 13 | 2025 | 779 | 1.260 |
Why?
|
| Atrial Natriuretic Factor | 11 | 2017 | 52 | 1.260 |
Why?
|
| Prognosis | 60 | 2024 | 4631 | 1.260 |
Why?
|
| Adult | 88 | 2025 | 29576 | 1.250 |
Why?
|
| Predictive Value of Tests | 39 | 2024 | 2154 | 1.250 |
Why?
|
| United States | 68 | 2025 | 10909 | 1.210 |
Why?
|
| Potassium | 6 | 2020 | 280 | 1.200 |
Why?
|
| Syncope | 8 | 2022 | 51 | 1.180 |
Why?
|
| Glycopeptides | 7 | 2018 | 25 | 1.180 |
Why?
|
| Polymers | 2 | 2019 | 107 | 1.150 |
Why?
|
| Point-of-Care Systems | 6 | 2024 | 172 | 1.110 |
Why?
|
| Warfarin | 11 | 2019 | 119 | 1.090 |
Why?
|
| Sensitivity and Specificity | 34 | 2021 | 2051 | 1.090 |
Why?
|
| Pyridines | 4 | 2015 | 230 | 1.070 |
Why?
|
| Hemodynamics | 8 | 2019 | 851 | 1.000 |
Why?
|
| Pyridones | 8 | 2019 | 118 | 1.000 |
Why?
|
| Pulmonary Edema | 4 | 2022 | 47 | 0.980 |
Why?
|
| Medicare | 5 | 2023 | 424 | 0.980 |
Why?
|
| Retrospective Studies | 61 | 2023 | 16345 | 0.950 |
Why?
|
| Protein Precursors | 5 | 2020 | 152 | 0.930 |
Why?
|
| Stroke Volume | 16 | 2021 | 488 | 0.930 |
Why?
|
| Creatine Kinase, MB Form | 10 | 2017 | 19 | 0.920 |
Why?
|
| Silicates | 3 | 2020 | 10 | 0.920 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 3 | 2017 | 32 | 0.920 |
Why?
|
| Heart Arrest | 5 | 2024 | 352 | 0.920 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2016 | 90 | 0.920 |
Why?
|
| Body Temperature | 2 | 2015 | 116 | 0.920 |
Why?
|
| Quality of Health Care | 10 | 2020 | 390 | 0.910 |
Why?
|
| Early Diagnosis | 7 | 2017 | 181 | 0.910 |
Why?
|
| Diuretics | 14 | 2021 | 171 | 0.900 |
Why?
|
| Percutaneous Coronary Intervention | 5 | 2021 | 254 | 0.900 |
Why?
|
| Natriuretic Agents | 6 | 2011 | 33 | 0.900 |
Why?
|
| Time Factors | 43 | 2021 | 6320 | 0.900 |
Why?
|
| Hypothermia, Induced | 2 | 2017 | 170 | 0.890 |
Why?
|
| Pyrazoles | 8 | 2019 | 305 | 0.890 |
Why?
|
| Infusions, Intravenous | 14 | 2017 | 556 | 0.870 |
Why?
|
| Immunoassay | 3 | 2025 | 130 | 0.870 |
Why?
|
| Pilot Projects | 12 | 2022 | 1397 | 0.870 |
Why?
|
| Accreditation | 5 | 2021 | 88 | 0.860 |
Why?
|
| Time-to-Treatment | 5 | 2018 | 186 | 0.820 |
Why?
|
| Antithrombins | 4 | 2019 | 56 | 0.820 |
Why?
|
| Phonocardiography | 4 | 2009 | 4 | 0.820 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2024 | 134 | 0.810 |
Why?
|
| Coronary Disease | 13 | 2006 | 674 | 0.810 |
Why?
|
| Societies, Medical | 10 | 2021 | 695 | 0.780 |
Why?
|
| Critical Pathways | 6 | 2019 | 76 | 0.770 |
Why?
|
| Aggression | 1 | 2024 | 223 | 0.770 |
Why?
|
| Ventricular Dysfunction, Left | 7 | 2020 | 366 | 0.760 |
Why?
|
| Treatment Outcome | 42 | 2024 | 12405 | 0.760 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 6 | 2018 | 596 | 0.750 |
Why?
|
| Blood Pressure | 9 | 2017 | 1364 | 0.730 |
Why?
|
| Analgesics, Opioid | 3 | 2022 | 415 | 0.730 |
Why?
|
| Severity of Illness Index | 24 | 2024 | 2902 | 0.720 |
Why?
|
| Clinical Protocols | 7 | 2017 | 241 | 0.720 |
Why?
|
| Biological Assay | 3 | 2020 | 103 | 0.710 |
Why?
|
| Noninvasive Ventilation | 2 | 2018 | 29 | 0.700 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2020 | 136 | 0.690 |
Why?
|
| Costs and Cost Analysis | 3 | 2017 | 164 | 0.670 |
Why?
|
| Angina Pectoris | 8 | 2016 | 57 | 0.670 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2016 | 31 | 0.660 |
Why?
|
| Observation | 9 | 2017 | 42 | 0.660 |
Why?
|
| Tachycardia, Supraventricular | 2 | 2024 | 109 | 0.660 |
Why?
|
| Risk Factors | 45 | 2023 | 10285 | 0.650 |
Why?
|
| Pneumonia, Bacterial | 1 | 2020 | 76 | 0.640 |
Why?
|
| Angioplasty, Balloon, Coronary | 10 | 2009 | 181 | 0.640 |
Why?
|
| Disease Management | 9 | 2021 | 525 | 0.640 |
Why?
|
| Cardiovascular Diseases | 13 | 2021 | 1951 | 0.640 |
Why?
|
| Decision Making | 4 | 2014 | 656 | 0.630 |
Why?
|
| Calcitonin | 2 | 2020 | 30 | 0.620 |
Why?
|
| Diabetes Mellitus | 7 | 2022 | 872 | 0.620 |
Why?
|
| Cardiography, Impedance | 3 | 2008 | 10 | 0.610 |
Why?
|
| Adrenomedullin | 6 | 2017 | 74 | 0.610 |
Why?
|
| Coronary Care Units | 4 | 2013 | 36 | 0.610 |
Why?
|
| Renin-Angiotensin System | 4 | 2020 | 101 | 0.610 |
Why?
|
| Nicardipine | 3 | 2015 | 18 | 0.610 |
Why?
|
| Labetalol | 3 | 2015 | 12 | 0.600 |
Why?
|
| Follow-Up Studies | 32 | 2021 | 5165 | 0.600 |
Why?
|
| Renal Insufficiency | 8 | 2014 | 237 | 0.600 |
Why?
|
| Decision Support Techniques | 5 | 2020 | 292 | 0.600 |
Why?
|
| ST Elevation Myocardial Infarction | 2 | 2018 | 113 | 0.580 |
Why?
|
| Double-Blind Method | 14 | 2020 | 1645 | 0.570 |
Why?
|
| Administration, Oral | 7 | 2019 | 682 | 0.570 |
Why?
|
| Consensus Development Conferences as Topic | 2 | 2017 | 39 | 0.570 |
Why?
|
| Coronary Artery Disease | 8 | 2023 | 790 | 0.570 |
Why?
|
| Triage | 8 | 2021 | 138 | 0.570 |
Why?
|
| Intracranial Hemorrhages | 2 | 2019 | 76 | 0.560 |
Why?
|
| Heart Failure, Systolic | 2 | 2009 | 32 | 0.550 |
Why?
|
| Posture | 2 | 2015 | 154 | 0.550 |
Why?
|
| Patient Admission | 11 | 2018 | 186 | 0.550 |
Why?
|
| Disinfection | 3 | 2024 | 26 | 0.550 |
Why?
|
| Health Care Costs | 8 | 2023 | 371 | 0.530 |
Why?
|
| Hospital Costs | 4 | 2017 | 179 | 0.530 |
Why?
|
| Patient Education as Topic | 2 | 2018 | 442 | 0.510 |
Why?
|
| ROC Curve | 14 | 2019 | 571 | 0.510 |
Why?
|
| Healthcare Disparities | 4 | 2017 | 432 | 0.510 |
Why?
|
| Intracranial Embolism | 4 | 2020 | 27 | 0.510 |
Why?
|
| Patient Care Management | 1 | 2016 | 67 | 0.500 |
Why?
|
| Cardiopulmonary Resuscitation | 3 | 2017 | 315 | 0.500 |
Why?
|
| Valsalva Maneuver | 1 | 2015 | 9 | 0.500 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2019 | 225 | 0.500 |
Why?
|
| Furosemide | 2 | 2021 | 38 | 0.490 |
Why?
|
| Ventricular Function, Left | 5 | 2021 | 506 | 0.490 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 512 | 0.490 |
Why?
|
| Blood Chemical Analysis | 3 | 2020 | 80 | 0.480 |
Why?
|
| Morphine | 3 | 2017 | 84 | 0.480 |
Why?
|
| Limit of Detection | 8 | 2025 | 63 | 0.480 |
Why?
|
| Acetaminophen | 2 | 2018 | 95 | 0.470 |
Why?
|
| Comorbidity | 13 | 2019 | 1532 | 0.470 |
Why?
|
| Defibrillators, Implantable | 2 | 2014 | 190 | 0.460 |
Why?
|
| Multicenter Studies as Topic | 8 | 2023 | 276 | 0.460 |
Why?
|
| Heart Sounds | 4 | 2006 | 7 | 0.460 |
Why?
|
| Research Design | 8 | 2019 | 693 | 0.460 |
Why?
|
| Consensus | 10 | 2019 | 645 | 0.450 |
Why?
|
| Sepsis | 2 | 2020 | 478 | 0.450 |
Why?
|
| Peroxidase | 2 | 2011 | 62 | 0.450 |
Why?
|
| Platelet Aggregation Inhibitors | 9 | 2020 | 268 | 0.440 |
Why?
|
| Calcium Channel Blockers | 2 | 2014 | 115 | 0.440 |
Why?
|
| Blood Pressure Determination | 2 | 2014 | 110 | 0.440 |
Why?
|
| Quality Assurance, Health Care | 4 | 2013 | 207 | 0.430 |
Why?
|
| Lipocalins | 1 | 2013 | 30 | 0.430 |
Why?
|
| Heart Auscultation | 3 | 2010 | 7 | 0.430 |
Why?
|
| Angina, Unstable | 8 | 2023 | 52 | 0.430 |
Why?
|
| Acute-Phase Proteins | 1 | 2013 | 47 | 0.430 |
Why?
|
| Medical History Taking | 1 | 2014 | 108 | 0.430 |
Why?
|
| Receptors, Cell Surface | 2 | 2013 | 469 | 0.430 |
Why?
|
| Hospitals, Urban | 1 | 2013 | 99 | 0.420 |
Why?
|
| Clinical Trials as Topic | 10 | 2015 | 1093 | 0.410 |
Why?
|
| Reference Values | 6 | 2025 | 710 | 0.410 |
Why?
|
| Critical Illness | 2 | 2014 | 602 | 0.400 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2020 | 728 | 0.400 |
Why?
|
| Algorithms | 12 | 2021 | 1624 | 0.390 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 7 | 2017 | 224 | 0.390 |
Why?
|
| Evidence-Based Medicine | 8 | 2018 | 635 | 0.380 |
Why?
|
| Infection Control | 2 | 2024 | 155 | 0.380 |
Why?
|
| Bronchodilator Agents | 2 | 2017 | 153 | 0.380 |
Why?
|
| Age Factors | 14 | 2018 | 2823 | 0.380 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2011 | 21 | 0.380 |
Why?
|
| Myocardial Revascularization | 6 | 2020 | 103 | 0.370 |
Why?
|
| Creatine Kinase | 7 | 2003 | 55 | 0.370 |
Why?
|
| Plant Development | 1 | 2011 | 5 | 0.370 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2024 | 105 | 0.370 |
Why?
|
| Ambulatory Care | 4 | 2021 | 388 | 0.370 |
Why?
|
| Antipyretics | 1 | 2011 | 9 | 0.370 |
Why?
|
| Diagnosis, Differential | 14 | 2021 | 1885 | 0.370 |
Why?
|
| Quality of Life | 3 | 2021 | 1944 | 0.360 |
Why?
|
| Cognition Disorders | 1 | 2015 | 553 | 0.360 |
Why?
|
| Insulin | 3 | 2023 | 1201 | 0.360 |
Why?
|
| Plants | 1 | 2011 | 46 | 0.360 |
Why?
|
| Constipation | 2 | 2022 | 116 | 0.360 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2024 | 1116 | 0.360 |
Why?
|
| Guidelines as Topic | 4 | 2016 | 197 | 0.350 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 2 | 2020 | 13 | 0.350 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2021 | 628 | 0.350 |
Why?
|
| Continuity of Patient Care | 2 | 2013 | 153 | 0.340 |
Why?
|
| Ultrasonography | 4 | 2019 | 933 | 0.340 |
Why?
|
| Hospital Units | 4 | 2019 | 17 | 0.340 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 544 | 0.340 |
Why?
|
| Confidence Intervals | 7 | 2010 | 285 | 0.340 |
Why?
|
| Asthma | 2 | 2017 | 748 | 0.340 |
Why?
|
| Mortality | 4 | 2019 | 238 | 0.340 |
Why?
|
| Incidence | 10 | 2020 | 3140 | 0.330 |
Why?
|
| Lipocalin-2 | 2 | 2024 | 29 | 0.330 |
Why?
|
| Cohort Studies | 16 | 2022 | 4808 | 0.330 |
Why?
|
| Auscultation | 2 | 2006 | 3 | 0.330 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 4 | 2009 | 43 | 0.320 |
Why?
|
| Exercise Test | 4 | 2020 | 254 | 0.320 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2009 | 55 | 0.320 |
Why?
|
| Logistic Models | 16 | 2018 | 1812 | 0.320 |
Why?
|
| Reproducibility of Results | 10 | 2025 | 2881 | 0.320 |
Why?
|
| Spain | 8 | 2024 | 59 | 0.320 |
Why?
|
| Physicians | 3 | 2022 | 581 | 0.310 |
Why?
|
| Professional Practice Gaps | 2 | 2020 | 15 | 0.310 |
Why?
|
| Outpatients | 2 | 2022 | 253 | 0.310 |
Why?
|
| Hygiene | 2 | 2023 | 26 | 0.300 |
Why?
|
| Lung Diseases | 2 | 2011 | 380 | 0.300 |
Why?
|
| Fever | 1 | 2011 | 298 | 0.300 |
Why?
|
| Cardiovascular Agents | 3 | 2014 | 88 | 0.300 |
Why?
|
| Fibrinolytic Agents | 3 | 2018 | 203 | 0.300 |
Why?
|
| Isoenzymes | 5 | 2003 | 226 | 0.300 |
Why?
|
| Risk | 3 | 2019 | 755 | 0.300 |
Why?
|
| Sex Factors | 10 | 2020 | 1287 | 0.300 |
Why?
|
| Nitroglycerin | 3 | 2010 | 22 | 0.290 |
Why?
|
| Myocardial Reperfusion | 2 | 2011 | 73 | 0.290 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 3 | 2019 | 16 | 0.290 |
Why?
|
| Europe | 9 | 2021 | 353 | 0.290 |
Why?
|
| Quality Improvement | 4 | 2024 | 641 | 0.290 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2017 | 729 | 0.290 |
Why?
|
| Aspirin | 6 | 2020 | 223 | 0.280 |
Why?
|
| Ischemic Attack, Transient | 2 | 2018 | 57 | 0.280 |
Why?
|
| Point-of-Care Testing | 2 | 2024 | 27 | 0.280 |
Why?
|
| Cardiac Catheterization | 8 | 2020 | 634 | 0.280 |
Why?
|
| Galectins | 2 | 2019 | 22 | 0.280 |
Why?
|
| Diagnostic Imaging | 4 | 2009 | 277 | 0.270 |
Why?
|
| Advisory Committees | 3 | 2016 | 153 | 0.270 |
Why?
|
| Insurance Claim Review | 2 | 2017 | 27 | 0.270 |
Why?
|
| Kidney | 2 | 2017 | 1356 | 0.270 |
Why?
|
| Echocardiography, Doppler | 1 | 2007 | 171 | 0.270 |
Why?
|
| Aftercare | 3 | 2023 | 147 | 0.270 |
Why?
|
| Heart Rate | 3 | 2021 | 590 | 0.270 |
Why?
|
| Cross-Sectional Studies | 9 | 2024 | 3436 | 0.260 |
Why?
|
| Acute Kidney Injury | 1 | 2013 | 633 | 0.260 |
Why?
|
| Prevalence | 8 | 2020 | 2448 | 0.260 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 678 | 0.260 |
Why?
|
| Endothelin-1 | 2 | 2017 | 40 | 0.260 |
Why?
|
| Propensity Score | 5 | 2018 | 216 | 0.260 |
Why?
|
| Cardiac Imaging Techniques | 2 | 2016 | 26 | 0.250 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2020 | 117 | 0.250 |
Why?
|
| Athletic Injuries | 2 | 2024 | 58 | 0.250 |
Why?
|
| Checklist | 2 | 2024 | 86 | 0.250 |
Why?
|
| Survival Rate | 11 | 2019 | 2060 | 0.240 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2025 | 35 | 0.240 |
Why?
|
| International Normalized Ratio | 1 | 2005 | 41 | 0.230 |
Why?
|
| Nasal Sprays | 1 | 2024 | 8 | 0.230 |
Why?
|
| Myocardial Ischemia | 5 | 2006 | 340 | 0.230 |
Why?
|
| Databases, Factual | 4 | 2017 | 1179 | 0.230 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2014 | 128 | 0.230 |
Why?
|
| Heart Ventricles | 1 | 2009 | 763 | 0.220 |
Why?
|
| Internationality | 3 | 2020 | 131 | 0.220 |
Why?
|
| Clinical Laboratory Services | 1 | 2024 | 19 | 0.220 |
Why?
|
| Kidney Diseases | 3 | 2021 | 478 | 0.220 |
Why?
|
| Heparin | 5 | 2017 | 226 | 0.220 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2023 | 5 | 0.210 |
Why?
|
| Biomedical Research | 4 | 2016 | 519 | 0.210 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 2 | 2020 | 32 | 0.210 |
Why?
|
| Glomerular Filtration Rate | 5 | 2020 | 500 | 0.210 |
Why?
|
| Survival Analysis | 8 | 2015 | 1507 | 0.210 |
Why?
|
| Lung | 3 | 2020 | 1488 | 0.210 |
Why?
|
| Intensive Care Units | 3 | 2018 | 490 | 0.210 |
Why?
|
| Area Under Curve | 5 | 2018 | 318 | 0.210 |
Why?
|
| Chi-Square Distribution | 8 | 2016 | 590 | 0.210 |
Why?
|
| Ethics Committees, Research | 1 | 2023 | 32 | 0.210 |
Why?
|
| Inpatients | 3 | 2017 | 497 | 0.210 |
Why?
|
| Violence | 1 | 2024 | 116 | 0.210 |
Why?
|
| Albuterol | 1 | 2023 | 53 | 0.210 |
Why?
|
| Delivery of Health Care | 3 | 2021 | 607 | 0.210 |
Why?
|
| American Heart Association | 3 | 2022 | 322 | 0.210 |
Why?
|
| Quality Indicators, Health Care | 2 | 2017 | 219 | 0.210 |
Why?
|
| Odds Ratio | 10 | 2013 | 1259 | 0.210 |
Why?
|
| Cardiotonic Agents | 3 | 2015 | 138 | 0.200 |
Why?
|
| Cholesterol, HDL | 1 | 2024 | 358 | 0.200 |
Why?
|
| Brain Injuries, Traumatic | 2 | 2018 | 381 | 0.200 |
Why?
|
| Hand Disinfection | 1 | 2022 | 16 | 0.200 |
Why?
|
| Long-Term Care | 1 | 2023 | 69 | 0.200 |
Why?
|
| Emergencies | 2 | 2003 | 172 | 0.200 |
Why?
|
| Self Care | 2 | 2021 | 215 | 0.200 |
Why?
|
| Multivariate Analysis | 9 | 2016 | 1439 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2018 | 2096 | 0.200 |
Why?
|
| Monocytes | 1 | 2024 | 351 | 0.200 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 664 | 0.200 |
Why?
|
| Cause of Death | 6 | 2018 | 474 | 0.200 |
Why?
|
| Railroads | 1 | 2022 | 3 | 0.200 |
Why?
|
| Lymphocytes | 1 | 2024 | 408 | 0.190 |
Why?
|
| Vitamin K | 2 | 2017 | 37 | 0.190 |
Why?
|
| Pain Clinics | 1 | 2021 | 4 | 0.190 |
Why?
|
| Hospitals | 5 | 2022 | 388 | 0.190 |
Why?
|
| Vaccination | 2 | 2024 | 955 | 0.190 |
Why?
|
| Systole | 3 | 2009 | 199 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 3 | 2016 | 509 | 0.190 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2021 | 29 | 0.190 |
Why?
|
| Young Adult | 9 | 2019 | 9051 | 0.190 |
Why?
|
| Heart Conduction System | 3 | 2009 | 146 | 0.190 |
Why?
|
| Seasons | 2 | 2024 | 310 | 0.190 |
Why?
|
| Transgender Persons | 1 | 2022 | 62 | 0.190 |
Why?
|
| Clinical Competence | 2 | 2009 | 1000 | 0.190 |
Why?
|
| Cerebral Hemorrhage | 2 | 2020 | 143 | 0.190 |
Why?
|
| Naltrexone | 1 | 2021 | 70 | 0.190 |
Why?
|
| Neutrophils | 1 | 2024 | 381 | 0.190 |
Why?
|
| Coronary Angiography | 4 | 2020 | 441 | 0.180 |
Why?
|
| Coronary Stenosis | 2 | 2015 | 76 | 0.180 |
Why?
|
| Carnitine | 1 | 2021 | 74 | 0.180 |
Why?
|
| Laboratories | 2 | 2024 | 82 | 0.180 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2021 | 77 | 0.180 |
Why?
|
| Pyuria | 1 | 2000 | 6 | 0.180 |
Why?
|
| Oliguria | 1 | 2000 | 19 | 0.180 |
Why?
|
| Neurophysiological Monitoring | 1 | 2021 | 37 | 0.170 |
Why?
|
| Blood Coagulation Tests | 2 | 2022 | 62 | 0.170 |
Why?
|
| Buprenorphine | 1 | 2021 | 95 | 0.170 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2020 | 49 | 0.170 |
Why?
|
| Cerebrovascular Disorders | 1 | 2021 | 122 | 0.170 |
Why?
|
| Myoglobin | 2 | 2011 | 107 | 0.170 |
Why?
|
| Hyperglycemia | 1 | 2022 | 223 | 0.170 |
Why?
|
| Equipment Contamination | 1 | 2020 | 37 | 0.170 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2019 | 9 | 0.170 |
Why?
|
| Drug Antagonism | 1 | 2019 | 12 | 0.170 |
Why?
|
| Stress Disorders, Traumatic | 1 | 2019 | 5 | 0.170 |
Why?
|
| Echocardiography | 3 | 2020 | 1052 | 0.170 |
Why?
|
| Antidotes | 1 | 2019 | 12 | 0.170 |
Why?
|
| Hospitals, Community | 1 | 2020 | 55 | 0.170 |
Why?
|
| Cystitis | 1 | 2000 | 49 | 0.170 |
Why?
|
| Thrombolytic Therapy | 4 | 2011 | 212 | 0.160 |
Why?
|
| Blood Cell Count | 1 | 2019 | 70 | 0.160 |
Why?
|
| Myocardium | 3 | 2014 | 998 | 0.160 |
Why?
|
| Case-Control Studies | 4 | 2019 | 3289 | 0.160 |
Why?
|
| Influenza Vaccines | 1 | 2024 | 479 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2020 | 1054 | 0.160 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2021 | 160 | 0.160 |
Why?
|
| Injections, Intravenous | 4 | 2017 | 250 | 0.160 |
Why?
|
| Heart Function Tests | 2 | 2017 | 56 | 0.160 |
Why?
|
| Health Status Indicators | 2 | 2010 | 122 | 0.160 |
Why?
|
| Drug Approval | 1 | 2019 | 43 | 0.160 |
Why?
|
| Adolescent | 16 | 2019 | 19343 | 0.150 |
Why?
|
| Critical Care | 4 | 2015 | 656 | 0.150 |
Why?
|
| Sleep Wake Disorders | 1 | 2021 | 167 | 0.150 |
Why?
|
| Drug Administration Schedule | 3 | 2016 | 727 | 0.150 |
Why?
|
| Pain Measurement | 3 | 2017 | 352 | 0.150 |
Why?
|
| Glucose | 1 | 2023 | 876 | 0.150 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 260 | 0.150 |
Why?
|
| Mental Disorders | 2 | 2024 | 827 | 0.150 |
Why?
|
| Erythrocyte Transfusion | 1 | 2019 | 129 | 0.150 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2018 | 58 | 0.150 |
Why?
|
| Codeine | 1 | 2018 | 24 | 0.150 |
Why?
|
| Temperature | 1 | 2019 | 303 | 0.150 |
Why?
|
| Global Health | 4 | 2019 | 561 | 0.150 |
Why?
|
| Hydrocodone | 1 | 2018 | 36 | 0.150 |
Why?
|
| Influenza, Human | 1 | 2024 | 658 | 0.150 |
Why?
|
| Blood Proteins | 2 | 2019 | 124 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2017 | 1692 | 0.150 |
Why?
|
| Cardiology Service, Hospital | 1 | 2017 | 15 | 0.140 |
Why?
|
| Head | 1 | 2018 | 103 | 0.140 |
Why?
|
| Respiration, Artificial | 3 | 2015 | 462 | 0.140 |
Why?
|
| Coronary Artery Bypass | 5 | 2014 | 516 | 0.140 |
Why?
|
| Disease Transmission, Infectious | 1 | 2018 | 84 | 0.140 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 13 | 0.140 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 184 | 0.140 |
Why?
|
| Mass Screening | 2 | 2016 | 783 | 0.140 |
Why?
|
| Telephone | 1 | 2018 | 110 | 0.140 |
Why?
|
| Medically Uninsured | 1 | 2018 | 73 | 0.140 |
Why?
|
| Potassium, Dietary | 1 | 2017 | 12 | 0.140 |
Why?
|
| Calcium Gluconate | 1 | 2017 | 6 | 0.140 |
Why?
|
| Disease Progression | 8 | 2020 | 2060 | 0.140 |
Why?
|
| Secondary Prevention | 2 | 2018 | 217 | 0.140 |
Why?
|
| Finland | 1 | 2017 | 42 | 0.140 |
Why?
|
| Iron | 1 | 2019 | 266 | 0.140 |
Why?
|
| New Zealand | 4 | 2019 | 51 | 0.140 |
Why?
|
| Motor Vehicles | 3 | 2021 | 9 | 0.140 |
Why?
|
| Drug Prescriptions | 2 | 2016 | 221 | 0.140 |
Why?
|
| Transitional Care | 1 | 2017 | 17 | 0.130 |
Why?
|
| Circadian Rhythm | 1 | 2019 | 271 | 0.130 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 491 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2023 | 835 | 0.130 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2017 | 62 | 0.130 |
Why?
|
| Diabetic Angiopathies | 1 | 2017 | 65 | 0.130 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2016 | 53 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 2 | 2002 | 877 | 0.130 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 1329 | 0.130 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 2 | 2015 | 32 | 0.130 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 91 | 0.130 |
Why?
|
| Abdominal Pain | 1 | 2018 | 310 | 0.130 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2016 | 109 | 0.130 |
Why?
|
| Electroencephalography | 1 | 2021 | 865 | 0.130 |
Why?
|
| Accidents, Traffic | 3 | 2021 | 108 | 0.130 |
Why?
|
| Drug Utilization | 3 | 2012 | 161 | 0.130 |
Why?
|
| Natriuretic Peptides | 1 | 2015 | 8 | 0.130 |
Why?
|
| Depressive Disorder, Major | 1 | 2021 | 399 | 0.130 |
Why?
|
| Symptom Flare Up | 1 | 2015 | 24 | 0.120 |
Why?
|
| Heart | 1 | 2020 | 712 | 0.120 |
Why?
|
| Frail Elderly | 1 | 2016 | 96 | 0.120 |
Why?
|
| Intubation, Intratracheal | 2 | 2016 | 290 | 0.120 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2004 | 62 | 0.120 |
Why?
|
| Texas | 3 | 2018 | 3586 | 0.120 |
Why?
|
| Geriatric Assessment | 1 | 2016 | 174 | 0.120 |
Why?
|
| Lipids | 2 | 2016 | 518 | 0.120 |
Why?
|
| Thiazoles | 1 | 2015 | 98 | 0.120 |
Why?
|
| Smoking Cessation | 2 | 2014 | 198 | 0.120 |
Why?
|
| Drug Interactions | 1 | 2015 | 253 | 0.120 |
Why?
|
| beta-Alanine | 1 | 2014 | 8 | 0.120 |
Why?
|
| Renal Dialysis | 2 | 2002 | 852 | 0.110 |
Why?
|
| Fibrosis | 2 | 2014 | 429 | 0.110 |
Why?
|
| Morpholines | 1 | 2014 | 57 | 0.110 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2015 | 90 | 0.110 |
Why?
|
| Neuroimaging | 1 | 2017 | 340 | 0.110 |
Why?
|
| Thiophenes | 1 | 2014 | 59 | 0.110 |
Why?
|
| Drug Monitoring | 1 | 2015 | 172 | 0.110 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 224 | 0.110 |
Why?
|
| Internet | 2 | 2007 | 375 | 0.110 |
Why?
|
| Patient Selection | 3 | 2008 | 696 | 0.110 |
Why?
|
| Syndrome | 6 | 2009 | 1120 | 0.110 |
Why?
|
| Data Collection | 2 | 2013 | 381 | 0.110 |
Why?
|
| Radiography, Thoracic | 3 | 2014 | 152 | 0.110 |
Why?
|
| Program Evaluation | 1 | 2016 | 444 | 0.110 |
Why?
|
| Matched-Pair Analysis | 1 | 2013 | 27 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2014 | 132 | 0.110 |
Why?
|
| Statistics, Nonparametric | 3 | 2016 | 431 | 0.110 |
Why?
|
| Electric Impedance | 2 | 2011 | 58 | 0.110 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2014 | 87 | 0.110 |
Why?
|
| Recurrence | 3 | 2019 | 1421 | 0.110 |
Why?
|
| Cardiac Care Facilities | 2 | 2015 | 10 | 0.110 |
Why?
|
| Body Surface Potential Mapping | 2 | 2010 | 12 | 0.100 |
Why?
|
| Ventricular Remodeling | 1 | 2014 | 181 | 0.100 |
Why?
|
| RNA | 1 | 2016 | 570 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 815 | 0.100 |
Why?
|
| Ohio | 4 | 2005 | 86 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 1358 | 0.100 |
Why?
|
| Monitoring, Physiologic | 2 | 2021 | 377 | 0.100 |
Why?
|
| Body Mass Index | 3 | 2013 | 1563 | 0.100 |
Why?
|
| Software | 1 | 2017 | 683 | 0.100 |
Why?
|
| Radiology | 2 | 2016 | 106 | 0.100 |
Why?
|
| Electronic Health Records | 2 | 2017 | 723 | 0.100 |
Why?
|
| Inflammation | 2 | 2023 | 1432 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2014 | 171 | 0.100 |
Why?
|
| Physical Fitness | 1 | 2012 | 90 | 0.100 |
Why?
|
| Cardiac Output | 2 | 2010 | 171 | 0.100 |
Why?
|
| Nephrology | 1 | 2013 | 146 | 0.100 |
Why?
|
| Gene Expression | 1 | 2016 | 1562 | 0.090 |
Why?
|
| Veterans | 3 | 2019 | 1753 | 0.090 |
Why?
|
| Ethanol | 1 | 2023 | 163 | 0.090 |
Why?
|
| Blood Urea Nitrogen | 2 | 2009 | 73 | 0.090 |
Why?
|
| Morbidity | 2 | 2010 | 248 | 0.090 |
Why?
|
| Coronary Vessels | 1 | 2015 | 541 | 0.090 |
Why?
|
| Hybrid Vigor | 1 | 2011 | 1 | 0.090 |
Why?
|
| RNA, Plant | 1 | 2011 | 8 | 0.090 |
Why?
|
| MADS Domain Proteins | 1 | 2011 | 3 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2014 | 243 | 0.090 |
Why?
|
| Flowers | 1 | 2011 | 8 | 0.090 |
Why?
|
| Genome, Plant | 1 | 2011 | 23 | 0.090 |
Why?
|
| Edible Grain | 1 | 2011 | 45 | 0.090 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 2011 | 47 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 1267 | 0.090 |
Why?
|
| Proteins | 1 | 2016 | 1036 | 0.090 |
Why?
|
| Pregnancy Proteins | 1 | 2011 | 13 | 0.090 |
Why?
|
| Laryngeal Masks | 1 | 2011 | 19 | 0.090 |
Why?
|
| Endotoxins | 1 | 2011 | 48 | 0.090 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2010 | 5 | 0.090 |
Why?
|
| Combined Modality Therapy | 3 | 2009 | 1240 | 0.090 |
Why?
|
| Arabidopsis Proteins | 1 | 2011 | 40 | 0.090 |
Why?
|
| Enoxaparin | 2 | 2017 | 42 | 0.090 |
Why?
|
| Kidney Function Tests | 2 | 2008 | 126 | 0.090 |
Why?
|
| RNA, Untranslated | 1 | 2011 | 113 | 0.090 |
Why?
|
| Arabidopsis | 1 | 2011 | 71 | 0.090 |
Why?
|
| Dihydropyridines | 1 | 2010 | 8 | 0.090 |
Why?
|
| Vascular Resistance | 1 | 2010 | 189 | 0.080 |
Why?
|
| Academic Medical Centers | 2 | 2004 | 307 | 0.080 |
Why?
|
| Hypotension | 2 | 2017 | 188 | 0.080 |
Why?
|
| France | 2 | 2019 | 80 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2013 | 541 | 0.080 |
Why?
|
| Singapore | 4 | 2016 | 16 | 0.080 |
Why?
|
| Likelihood Functions | 2 | 2006 | 114 | 0.080 |
Why?
|
| Decision Trees | 2 | 2016 | 49 | 0.080 |
Why?
|
| Clinical Decision-Making | 2 | 2024 | 266 | 0.080 |
Why?
|
| Electric Countershock | 1 | 2009 | 67 | 0.080 |
Why?
|
| Information Services | 1 | 2009 | 21 | 0.080 |
Why?
|
| House Calls | 2 | 2021 | 38 | 0.080 |
Why?
|
| Cardiovascular System | 1 | 2010 | 106 | 0.080 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 660 | 0.080 |
Why?
|
| Observational Studies as Topic | 2 | 2020 | 88 | 0.080 |
Why?
|
| Health Care Surveys | 1 | 2009 | 288 | 0.070 |
Why?
|
| Alcoholism | 1 | 1990 | 231 | 0.070 |
Why?
|
| Methamphetamine | 1 | 2008 | 32 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2014 | 771 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2011 | 759 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2009 | 1017 | 0.070 |
Why?
|
| Central Nervous System Stimulants | 1 | 2008 | 127 | 0.070 |
Why?
|
| Chromatin | 1 | 2011 | 550 | 0.070 |
Why?
|
| Australia | 2 | 2019 | 138 | 0.070 |
Why?
|
| Administration, Inhalation | 1 | 2007 | 180 | 0.070 |
Why?
|
| Contraindications | 1 | 2007 | 78 | 0.070 |
Why?
|
| Cocaine | 1 | 2008 | 207 | 0.070 |
Why?
|
| Exercise | 1 | 2012 | 817 | 0.070 |
Why?
|
| Heart Murmurs | 1 | 2006 | 15 | 0.070 |
Why?
|
| Sampling Studies | 1 | 2006 | 77 | 0.070 |
Why?
|
| Administrative Claims, Healthcare | 2 | 2017 | 15 | 0.070 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2011 | 994 | 0.060 |
Why?
|
| Insurance, Health | 2 | 2004 | 138 | 0.060 |
Why?
|
| Asia | 2 | 2020 | 107 | 0.060 |
Why?
|
| Heart Diseases | 1 | 2011 | 491 | 0.060 |
Why?
|
| Hypertension, Pulmonary | 1 | 2011 | 436 | 0.060 |
Why?
|
| Linear Models | 2 | 2013 | 681 | 0.060 |
Why?
|
| Specialties, Nursing | 1 | 2005 | 3 | 0.060 |
Why?
|
| Medicaid | 1 | 2008 | 242 | 0.060 |
Why?
|
| Tertiary Care Centers | 2 | 2017 | 235 | 0.060 |
Why?
|
| Creatinine | 4 | 2014 | 390 | 0.060 |
Why?
|
| Metabolomics | 2 | 2021 | 422 | 0.060 |
Why?
|
| Documentation | 2 | 2004 | 115 | 0.060 |
Why?
|
| Hospital Bed Capacity | 2 | 2016 | 25 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2013 | 1115 | 0.060 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2005 | 79 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2011 | 1008 | 0.060 |
Why?
|
| Age Distribution | 3 | 2015 | 415 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2011 | 1497 | 0.060 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2004 | 50 | 0.060 |
Why?
|
| Obesity | 2 | 2013 | 2237 | 0.060 |
Why?
|
| Home Care Services | 1 | 2024 | 68 | 0.060 |
Why?
|
| HIV Infections | 1 | 2016 | 1894 | 0.050 |
Why?
|
| Economics, Hospital | 1 | 2003 | 7 | 0.050 |
Why?
|
| Coronary Thrombosis | 1 | 2003 | 34 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2024 | 250 | 0.050 |
Why?
|
| Diastole | 1 | 2004 | 175 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2017 | 1165 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 1 | 2004 | 136 | 0.050 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2016 | 459 | 0.050 |
Why?
|
| Shock, Cardiogenic | 2 | 2015 | 192 | 0.050 |
Why?
|
| Neurotransmitter Agents | 1 | 2004 | 147 | 0.050 |
Why?
|
| Fractures, Bone | 2 | 1995 | 186 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2023 | 110 | 0.050 |
Why?
|
| Physical Examination | 3 | 2014 | 160 | 0.050 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2016 | 23 | 0.050 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2003 | 95 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2004 | 122 | 0.050 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2024 | 223 | 0.050 |
Why?
|
| Electrophysiology | 1 | 2003 | 270 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 232 | 0.050 |
Why?
|
| Kansas | 1 | 2021 | 6 | 0.050 |
Why?
|
| Prescriptions | 1 | 2021 | 40 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 287 | 0.050 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2021 | 47 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2000 | 824 | 0.040 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2020 | 22 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 241 | 0.040 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2020 | 46 | 0.040 |
Why?
|
| Blood Culture | 1 | 2020 | 30 | 0.040 |
Why?
|
| Peptides | 1 | 2003 | 798 | 0.040 |
Why?
|
| Uterine Hemorrhage | 1 | 2020 | 43 | 0.040 |
Why?
|
| Medical Records | 2 | 2006 | 192 | 0.040 |
Why?
|
| Georgia | 1 | 2019 | 30 | 0.040 |
Why?
|
| Netherlands | 1 | 2019 | 38 | 0.040 |
Why?
|
| Health Status | 1 | 2021 | 376 | 0.040 |
Why?
|
| Luminescent Measurements | 1 | 2019 | 57 | 0.040 |
Why?
|
| Radiography | 3 | 2016 | 821 | 0.040 |
Why?
|
| Meperidine | 1 | 1999 | 8 | 0.040 |
Why?
|
| Ureteral Calculi | 1 | 1999 | 15 | 0.040 |
Why?
|
| Colic | 1 | 1999 | 9 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2011 | 780 | 0.040 |
Why?
|
| Judgment | 1 | 2018 | 36 | 0.040 |
Why?
|
| Metabolome | 1 | 2021 | 293 | 0.040 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2018 | 21 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2015 | 1190 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2018 | 105 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2021 | 434 | 0.040 |
Why?
|
| Abdomen | 1 | 2018 | 127 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 2018 | 207 | 0.040 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 1999 | 72 | 0.040 |
Why?
|
| Telemedicine | 2 | 2021 | 435 | 0.040 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2017 | 57 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2018 | 268 | 0.040 |
Why?
|
| Reference Standards | 1 | 2018 | 238 | 0.030 |
Why?
|
| Military Personnel | 1 | 2019 | 210 | 0.030 |
Why?
|
| Forecasting | 2 | 2014 | 351 | 0.030 |
Why?
|
| Patient Discharge Summaries | 1 | 2017 | 10 | 0.030 |
Why?
|
| Narcotics | 1 | 2017 | 63 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 1586 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2018 | 419 | 0.030 |
Why?
|
| Probability | 2 | 2009 | 320 | 0.030 |
Why?
|
| Vital Signs | 1 | 2016 | 20 | 0.030 |
Why?
|
| Drug Utilization Review | 1 | 1996 | 33 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 3729 | 0.030 |
Why?
|
| Health Personnel | 2 | 2014 | 505 | 0.030 |
Why?
|
| Angiography | 1 | 2016 | 215 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 71 | 0.030 |
Why?
|
| Brain Ischemia | 1 | 2018 | 262 | 0.030 |
Why?
|
| Foot Injuries | 1 | 1995 | 7 | 0.030 |
Why?
|
| Smoking | 2 | 2012 | 1046 | 0.030 |
Why?
|
| Pravastatin | 1 | 2015 | 22 | 0.030 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2017 | 95 | 0.030 |
Why?
|
| Ankle Injuries | 1 | 1995 | 33 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 183 | 0.030 |
Why?
|
| Nurse's Role | 1 | 2015 | 31 | 0.030 |
Why?
|
| Knee Injuries | 1 | 1995 | 40 | 0.030 |
Why?
|
| Counseling | 1 | 2017 | 218 | 0.030 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2017 | 128 | 0.030 |
Why?
|
| Vascular Calcification | 1 | 2015 | 56 | 0.030 |
Why?
|
| Program Development | 1 | 2016 | 186 | 0.030 |
Why?
|
| Directive Counseling | 1 | 2014 | 24 | 0.030 |
Why?
|
| Sex Distribution | 2 | 2006 | 303 | 0.030 |
Why?
|
| Urban Population | 1 | 2016 | 226 | 0.030 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2015 | 122 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2015 | 142 | 0.030 |
Why?
|
| Vasodilation | 1 | 2015 | 191 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2016 | 278 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2015 | 361 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 337 | 0.030 |
Why?
|
| Public Health | 1 | 2016 | 262 | 0.030 |
Why?
|
| Drug Design | 1 | 2014 | 148 | 0.030 |
Why?
|
| Hypolipidemic Agents | 1 | 2014 | 180 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2017 | 672 | 0.030 |
Why?
|
| European Union | 1 | 2012 | 12 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2017 | 542 | 0.030 |
Why?
|
| Pneumonia, Aspiration | 1 | 1992 | 18 | 0.020 |
Why?
|
| Pharynx | 1 | 1992 | 64 | 0.020 |
Why?
|
| Depression | 1 | 2020 | 1236 | 0.020 |
Why?
|
| Oxygen | 1 | 2015 | 553 | 0.020 |
Why?
|
| Placenta Growth Factor | 1 | 2011 | 11 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2014 | 759 | 0.020 |
Why?
|
| England | 1 | 2011 | 60 | 0.020 |
Why?
|
| Americas | 1 | 2011 | 50 | 0.020 |
Why?
|
| Foreign Bodies | 1 | 1992 | 104 | 0.020 |
Why?
|
| Italy | 1 | 2011 | 99 | 0.020 |
Why?
|
| Evidence-Based Emergency Medicine | 1 | 2010 | 5 | 0.020 |
Why?
|
| Emergency Medical Technicians | 1 | 2011 | 45 | 0.020 |
Why?
|
| Intubation | 1 | 1990 | 17 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 133 | 0.020 |
Why?
|
| California | 1 | 2010 | 128 | 0.020 |
Why?
|
| History, 19th Century | 1 | 2011 | 116 | 0.020 |
Why?
|
| Airway Obstruction | 1 | 1992 | 165 | 0.020 |
Why?
|
| Animals | 4 | 2015 | 34057 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2009 | 28 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 131 | 0.020 |
Why?
|
| Atrial Flutter | 1 | 2009 | 32 | 0.020 |
Why?
|
| Necrosis | 1 | 2010 | 208 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 1990 | 277 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2009 | 56 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2011 | 383 | 0.020 |
Why?
|
| Equipment Design | 1 | 2011 | 596 | 0.020 |
Why?
|
| Education | 1 | 2009 | 109 | 0.020 |
Why?
|
| Esophagus | 1 | 1990 | 216 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 608 | 0.020 |
Why?
|
| Respiratory Sounds | 1 | 2008 | 68 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 732 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2008 | 71 | 0.020 |
Why?
|
| Brain | 1 | 2019 | 2994 | 0.020 |
Why?
|
| Crowding | 1 | 2007 | 9 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2009 | 375 | 0.020 |
Why?
|
| Benchmarking | 1 | 2008 | 134 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2006 | 28 | 0.020 |
Why?
|
| Models, Cardiovascular | 1 | 2008 | 182 | 0.020 |
Why?
|
| Heart-Assist Devices | 1 | 2015 | 1022 | 0.020 |
Why?
|
| Anemia | 1 | 2009 | 339 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2008 | 472 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 332 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2006 | 218 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2004 | 256 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2010 | 805 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 4353 | 0.010 |
Why?
|
| Sodium | 1 | 2005 | 295 | 0.010 |
Why?
|
| Factor Xa | 1 | 2004 | 17 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2005 | 309 | 0.010 |
Why?
|
| Stents | 1 | 2009 | 890 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2003 | 315 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2003 | 265 | 0.010 |
Why?
|
| Catheter Ablation | 1 | 2004 | 236 | 0.010 |
Why?
|
| Telemetry | 1 | 2000 | 27 | 0.010 |
Why?
|
| Tolmetin | 1 | 1999 | 1 | 0.010 |
Why?
|
| Ketorolac Tromethamine | 1 | 1999 | 2 | 0.010 |
Why?
|
| Tromethamine | 1 | 1999 | 9 | 0.010 |
Why?
|
| Urography | 1 | 1999 | 31 | 0.010 |
Why?
|
| Ketorolac | 1 | 1999 | 13 | 0.010 |
Why?
|
| Research Support as Topic | 1 | 1999 | 63 | 0.010 |
Why?
|
| Medical Records Systems, Computerized | 1 | 1999 | 166 | 0.010 |
Why?
|
| Suburban Health Services | 1 | 1996 | 1 | 0.010 |
Why?
|
| Michigan | 1 | 1996 | 42 | 0.010 |
Why?
|
| Ontario | 1 | 1995 | 64 | 0.010 |
Why?
|
| Physicians, Women | 1 | 1996 | 47 | 0.010 |
Why?
|
| Women's Health | 1 | 1996 | 133 | 0.010 |
Why?
|
| Mental Status Schedule | 1 | 1994 | 44 | 0.010 |
Why?
|
| Emergency Services, Psychiatric | 1 | 1994 | 20 | 0.010 |
Why?
|
| Pulmonary Gas Exchange | 1 | 1990 | 29 | 0.010 |
Why?
|
| Heart Massage | 1 | 1990 | 30 | 0.010 |
Why?
|
| Dogs | 1 | 1990 | 768 | 0.000 |
Why?
|
| Models, Biological | 1 | 1990 | 1458 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1994 | 14019 | 0.000 |
Why?
|
| Child | 1 | 1994 | 24410 | 0.000 |
Why?
|